Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 04, 2018 08:00 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Appoints Wen Bo Wang, Ph.D. as Senior Vice President, Technical Operations

SAN DIEGO, Oct. 04, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and...
September 25, 2018 16:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

SAN DIEGO, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
September 25, 2018 08:00 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
September 20, 2018 23:37 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Announces Pricing of Public Offering of Common Stock

SAN DIEGO, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
September 20, 2018 16:11 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Announces Proposed Public Offering of Common Stock

SAN DIEGO, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
September 17, 2018 19:00 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Announces Strategic Collaboration with ONO Pharmaceutical to Develop Off-the-Shelf, iPSC-derived CAR-T Cell Cancer Immunotherapies

SAN DIEGO, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
September 13, 2018 08:00 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Enters into Exclusive License Agreement with Gladstone Institutes for CRISPR-based Cellular Reprogramming

SAN DIEGO, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
August 29, 2018 16:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
August 07, 2018 16:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics to Present at the 2018 Wedbush PacGrow Healthcare Conference

SAN DIEGO, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
August 06, 2018 16:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Reports Second Quarter 2018 Financial Results and Highlights Operational Progress

Treated 20th Subject in Phase 2 PROTECT Study of ProTmune Opened Second Site for Enrollment of FATE-NK100 DIMENSION Study Submitted First-of-Kind IND to FDA for Universal Off-the-Shelf NK Cell...